Maly Nathalie Oron, MD
Pulmonary Disease · Los Altos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Dominican Hospital · El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Oron’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A161446 · Current
Licensed to practise in California · since 2019 · expires 2027-03-31 · Ben-Gurion University of the Negev-Irving and Joyce Goldman School of Med.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$194,199
Medicare paid this office $194,199 for 615 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 316 | $64,647 | $99 |
| Critical care, first 30-74 minutes | 81 | $33,150 | $184 |
| New patient visit (60+ min) | 82 | $14,622 | $178 |
| Long return visit (40+ min) | 62 | $14,258 | $140 |
| Test to examine how well the lungs exchange gases | 220 | $12,068 | $49 |
See all 19 services
| Return visit (30+ min) | 316 | $64,647 | $99 |
| Critical care, first 30-74 minutes | 81 | $33,150 | $184 |
| New patient visit (60+ min) | 82 | $14,622 | $178 |
| Long return visit (40+ min) | 62 | $14,258 | $140 |
| Test to examine how well the lungs exchange gases | 220 | $12,068 | $49 |
| Test to determine lung volumes using sensors | 206 | $11,391 | $49 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 253 | $9,519 | $33 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 272 | $6,970 | $13 |
| New patient visit (45+ min) | 35 | $4,785 | $137 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 14 | $4,071 | $291 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,830 | $106 |
| Influenza vaccine, inactivated | 39 | $3,191 | $82 |
| Short return visit (20+ min) | 47 | $2,761 | $55 |
| Administration of influenza virus vaccine | 45 | $1,558 | $35 |
| Critical care, each additional 30 minutes | 12 | $1,402 | $93 |
| Test to measure the level of nitric oxide gas | 53 | $1,021 | $18 |
| Test to determine lung volumes using gas dilution or washout | 16 | $651 | $41 |
| Administration of pneumococcal vaccine | 17 | $589 | $35 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 28 | $94 | $3 |
Who their Medicare patients are
615 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 15% · Women 57% · Also on Medicaid 16% · Health risk score 1.68. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 70% · COPD 40% · Coronary heart disease 30% · Atrial fibrillation 30% · Chronic kidney disease 27% · Depression 25% · Diabetes 24% · Heart failure 23% · Cancer 22% · Stroke 11% · Dementia 8%.
The office billed $891,911, Medicare allowed $257,178 and paid $194,199; for 2,734 services of 40 kinds; $8,001 of it was for drugs given in the office and $186,198 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 615 | 2,734 | 76 | 1.68 | $891,911 | $194,199 |
| 2023 | 591 | 2,034 | 77 | 1.70 | $778,145 | $190,687 |
| 2022 | 451 | 1,649 | 77 | 1.70 | $599,543 | $161,207 |
| 2021 | 460 | 1,600 | 76 | 1.63 | $671,082 | $173,108 |
| 2020 | 383 | 1,241 | 76 | 1.81 | $473,904 | $122,121 |
| 2019 | 105 | 333 | 75 | 1.61 | $85,326 | $24,099 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 278 | $58,705 | $102 |
| Critical care, first 30-74 minutes | 86 | $33,909 | $191 |
| New patient visit (60+ min) | 82 | $14,812 | $181 |
| Long return visit (40+ min) | 49 | $12,075 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $10,460 | $108 |
| Test to examine how well the lungs exchange gases | 167 | $9,628 | $52 |
| Short return visit (20+ min) | 106 | $9,150 | $73 |
| Test to determine lung volumes using sensors | 161 | $9,089 | $50 |
| New patient visit (45+ min) | 56 | $7,876 | $141 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 184 | $7,059 | $35 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 76 | $5,739 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,079 | $162 |
| Administration of influenza virus vaccine | 78 | $2,694 | $34 |
| Administration of pneumococcal vaccine | 12 | $409 | $34 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 19 | $69 | $3 |
2022: 15 services
| Return visit (30+ min) | 265 | $59,936 | $106 |
| Critical care, first 30-74 minutes | 51 | $24,210 | $200 |
| Long return visit (40+ min) | 72 | $15,288 | $159 |
| New patient visit (60+ min) | 54 | $10,541 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $8,776 | $94 |
| Short return visit (20+ min) | 79 | $7,375 | $76 |
| New patient visit (45+ min) | 46 | $6,605 | $144 |
| Test to examine how well the lungs exchange gases | 114 | $6,273 | $52 |
| Test to determine lung volumes using sensors | 108 | $5,550 | $49 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 115 | $4,034 | $33 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 38 | $2,670 | $70 |
| Administration of influenza virus vaccine | 40 | $1,396 | $34 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 33 | $750 | $21 |
| Administration of pneumococcal vaccine | 14 | $477 | $34 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 17 | $57 | $3 |
2021: 17 services
| Critical care, first 30-74 minutes | 99 | $52,763 | $200 |
| Return visit (30+ min) | 192 | $39,726 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $13,555 | $98 |
| New patient visit (45+ min) | 85 | $11,859 | $140 |
| Long return visit (40+ min) | 54 | $11,457 | $157 |
| New patient visit (60+ min) | 42 | $8,169 | $194 |
| Test to examine how well the lungs exchange gases | 99 | $5,864 | $53 |
| Test to determine lung volumes using sensors | 90 | $4,906 | $48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 108 | $4,551 | $39 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,616 | $190 |
| Short return visit (20+ min) | 42 | $3,550 | $79 |
| Pneumococcal vaccine, 13-valent | 12 | $2,874 | $240 |
| Influenza vaccine split virus, preservative free | 36 | $2,349 | $65 |
| Administration of influenza virus vaccine | 40 | $768 | $19 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 26 | $538 | $21 |
| Administration of pneumococcal vaccine | 16 | $306 | $19 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 13 | $45 | $3 |
2020: 16 services
| Critical care, first 30-74 minutes | 88 | $44,630 | $202 |
| Return visit (30+ min) | 122 | $17,949 | $86 |
| New patient visit (45+ min) | 117 | $15,410 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $11,411 | $96 |
| Test to examine how well the lungs exchange gases | 78 | $4,007 | $49 |
| Test to determine lung volumes using sensors | 76 | $3,692 | $47 |
| Short return visit (20+ min) | 44 | $3,679 | $67 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 68 | $3,495 | $50 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,738 | $196 |
| Long return visit (40+ min) | 19 | $1,942 | $102 |
| Influenza vaccine split virus, preservative free | 31 | $1,862 | $60 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $1,137 | $67 |
| Administration of influenza virus vaccine | 34 | $704 | $21 |
| Test to measure expiratory airflow and volume | 19 | $618 | $33 |
| Administration of pneumococcal vaccine | 17 | $341 | $20 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 11 | $1 | None |
2019: 9 services
| New patient visit (45+ min) | 59 | $8,221 | $139 |
| Return visit (30+ min) | 42 | $5,029 | $93 |
| Long return visit (40+ min) | 17 | $2,111 | $124 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $1,774 | $54 |
| Test to examine how well the lungs exchange gases | 30 | $1,504 | $50 |
| Test to determine lung volumes using sensors | 27 | $1,311 | $49 |
| Influenza vaccine split virus, preservative free | 18 | $970 | $54 |
| Administration of influenza virus vaccine | 22 | $437 | $20 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 13 | $1 | None |
Medicaid work
$281 in 2024
Medicaid paid $281 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $281 |
| 2024 | 12 | 1 | 12 | $281 |
| 2023 | 85 | 1 | 18 | $3,598 |
| 2022 | 152 | 1 | 21 | $7,648 |
| 2021 | 83 | 1 | 15 | $5,051 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 85 | $3,598 |
2022
| Return visit (30+ min) | 152 | $7,648 |
2021
| Return visit (30+ min) | 83 | $5,051 |
Drugs they prescribed that Part D paid
$1,208,377
Pharmacies billed $1,208,377 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,592) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
963 generic and 1,629 brand-name prescriptions · $1,208,377 in drug cost · 172 antibiotic prescriptions to 89 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ofev | 27 | $340,696 | $12,618 |
| Trelegy Ellipta | 385 | $307,650 | $799 |
| Anoro Ellipta | 172 | $97,845 | $569 |
| Breo Ellipta | 203 | $92,575 | $456 |
| Spiriva Respimat | 54 | $36,195 | $670 |
See all 33 drugs
| Ofev | 27 | $340,696 | $12,618 |
| Trelegy Ellipta | 385 | $307,650 | $799 |
| Anoro Ellipta | 172 | $97,845 | $569 |
| Breo Ellipta | 203 | $92,575 | $456 |
| Spiriva Respimat | 54 | $36,195 | $670 |
| Incruse Ellipta | 79 | $35,058 | $444 |
| Arnuity Ellipta | 121 | $30,525 | $252 |
| Symbicort | 73 | $29,777 | $408 |
| Dulera | 45 | $26,831 | $596 |
| Stiolto Respimat | 43 | $26,168 | $609 |
| Advair Hfa | 64 | $24,584 | $384 |
| Fluticasone-Salmeterol | 82 | $15,089 | $184 |
| Combivent Respimat | 13 | $11,974 | $921 |
| Wixela Inhub | 123 | $11,564 | $94 |
| Breyna | 32 | $10,757 | $336 |
| Budesonide-Formoterol | 35 | $9,156 | $262 |
| Pirfenidone | 11 | $8,386 | $762 |
| Albuterol Sulfate Hfa | 222 | $7,146 | $32 |
| Fluticasone Propionate Hfa | 16 | $6,195 | $387 |
| Ventolin Hfa | 37 | $3,399 | $92 |
| Advair Diskus | 18 | $3,230 | $179 |
| Ipratropium | 28 | $1,317 | $47 |
| Montelukast | 61 | $1,087 | $18 |
| Roflumilast | 37 | $1,053 | $28 |
| Azithromycin | 91 | $1,021 | $11 |
| Prednisone | 188 | $828 | $4 |
| Fluticasone Propionate | 36 | $658 | $18 |
| Amoxicillin-Clavulanate Potass | 54 | $549 | $10 |
| Ethambutol | 34 | $526 | $15 |
| Azelastine | 12 | $476 | $40 |
| Omeprazole | 35 | $418 | $12 |
| Rifampin | 24 | $339 | $14 |
| Doxycycline Hyclate | 15 | $92 | $6 |
Year by year
| 2024 | 2,592 | 411 | 0% (0) | 63% | $1,208,377 |
| 2023 | 2,153 | 350 | 0% (0) | 65% | $1,279,422 |
| 2022 | 1,754 | 320 | None | 65% | $1,010,504 |
| 2021 | 1,279 | 252 | 0% (0) | 67% | $680,894 |
| 2020 | 863 | 180 | 0% (0) | 66% | $372,125 |
| 2019 | 171 | 67 | 0% (0) | 58% | $43,339 |
| 2018 | 27 | 15 | 0% (0) | 56% | $5,084 |
| 2016 | 29 | 17 | 0% (0) | None | $1,699 |
| 2015 | 73 | 33 | 0% (0) | None | $4,392 |
| 2014 | 18 | 11 | 0% (0) | None | $2,510 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Ofev | 35 | $458,173 | $13,091 |
| Trelegy Ellipta | 301 | $257,832 | $857 |
| Anoro Ellipta | 204 | $116,659 | $572 |
| Advair Hfa | 109 | $66,008 | $606 |
| Breo Ellipta | 123 | $61,094 | $497 |
| Symbicort | 83 | $51,004 | $615 |
| Spiriva Respimat | 60 | $39,278 | $655 |
| Incruse Ellipta | 81 | $34,488 | $426 |
| Stiolto Respimat | 37 | $32,821 | $887 |
| Advair Diskus | 51 | $25,828 | $506 |
| Arnuity Ellipta | 83 | $23,408 | $282 |
| Flovent Hfa | 24 | $15,292 | $637 |
| Fluticasone-Salmeterol | 50 | $14,296 | $286 |
| Wixela Inhub | 46 | $12,067 | $262 |
| Dulera | 17 | $8,539 | $502 |
| Eliquis | 13 | $7,804 | $600 |
| Alvesco | 13 | $7,750 | $596 |
| Budesonide-Formoterol | 17 | $7,534 | $443 |
| Albuterol Sulfate Hfa | 152 | $6,190 | $41 |
| Ventolin Hfa | 23 | $2,656 | $115 |
| Clotrimazole | 17 | $1,531 | $90 |
| Azithromycin | 82 | $1,440 | $18 |
| Montelukast | 74 | $1,191 | $16 |
| Fluticasone Propionate | 50 | $1,133 | $23 |
| Prednisone | 181 | $999 | $6 |
| Ipratropium | 20 | $745 | $37 |
| Amoxicillin-Clavulanate Potass | 30 | $494 | $16 |
| Omeprazole | 41 | $412 | $10 |
| Ethambutol | 16 | $379 | $24 |
| Rifampin | 13 | $234 | $18 |
| Doxycycline Hyclate | 12 | $115 | $10 |
2022: 27 drugs
| Ofev | 25 | $325,746 | $13,030 |
| Trelegy Ellipta | 181 | $155,234 | $858 |
| Breo Ellipta | 207 | $95,722 | $462 |
| Spiriva Respimat | 102 | $63,167 | $619 |
| Anoro Ellipta | 110 | $62,599 | $569 |
| Advair Hfa | 103 | $61,152 | $594 |
| Symbicort | 85 | $52,759 | $621 |
| Stiolto Respimat | 32 | $38,930 | $1,217 |
| Incruse Ellipta | 43 | $19,817 | $461 |
| Advair Diskus | 30 | $18,040 | $601 |
| Arnuity Ellipta | 41 | $11,991 | $292 |
| Wixela Inhub | 35 | $11,070 | $316 |
| Flovent Hfa | 17 | $10,652 | $627 |
| Serevent Diskus | 19 | $8,859 | $466 |
| Albuterol Sulfate Hfa | 131 | $8,607 | $66 |
| Eliquis | 13 | $8,379 | $645 |
| Budesonide-Formoterol | 11 | $4,923 | $448 |
| Ventolin Hfa | 35 | $3,255 | $93 |
| Clotrimazole | 16 | $1,270 | $79 |
| Montelukast | 61 | $1,191 | $20 |
| Prednisone | 131 | $859 | $7 |
| Omeprazole | 61 | $819 | $13 |
| Azithromycin | 55 | $813 | $15 |
| Fluticasone Propionate | 45 | $798 | $18 |
| Levocetirizine Dihydrochloride | 12 | $433 | $36 |
| Nystatin | 11 | $312 | $28 |
| Famotidine | 16 | $200 | $13 |
2021: 23 drugs
| Ofev | 16 | $193,197 | $12,075 |
| Breo Ellipta | 193 | $84,860 | $440 |
| Trelegy Ellipta | 106 | $77,116 | $728 |
| Anoro Ellipta | 113 | $65,299 | $578 |
| Spiriva Respimat | 96 | $65,295 | $680 |
| Advair Hfa | 67 | $42,613 | $636 |
| Symbicort | 71 | $42,534 | $599 |
| Stiolto Respimat | 23 | $26,949 | $1,172 |
| Incruse Ellipta | 30 | $13,955 | $465 |
| Advair Diskus | 20 | $11,927 | $596 |
| Wixela Inhub | 27 | $8,752 | $324 |
| Spiriva | 11 | $8,686 | $790 |
| Flovent Hfa | 16 | $6,709 | $419 |
| Albuterol Sulfate Hfa | 91 | $5,819 | $64 |
| Dulera | 14 | $4,970 | $355 |
| Fluticasone-Salmeterol | 12 | $2,990 | $249 |
| Ventolin Hfa | 16 | $1,534 | $96 |
| Omeprazole | 73 | $1,101 | $15 |
| Montelukast | 58 | $833 | $14 |
| Fluticasone Propionate | 32 | $690 | $22 |
| Prednisone | 86 | $514 | $6 |
| Azithromycin | 26 | $353 | $14 |
| Levocetirizine Dihydrochloride | 11 | $97 | $9 |
2020: 17 drugs
| Breo Ellipta | 189 | $79,408 | $420 |
| Anoro Ellipta | 95 | $54,480 | $573 |
| Spiriva Respimat | 52 | $41,338 | $795 |
| Symbicort | 49 | $34,170 | $697 |
| Trelegy Ellipta | 31 | $20,583 | $664 |
| Stiolto Respimat | 12 | $15,114 | $1,259 |
| Flovent Hfa | 22 | $11,616 | $528 |
| Advair Hfa | 18 | $10,482 | $582 |
| Advair Diskus | 13 | $9,406 | $724 |
| Wixela Inhub | 24 | $5,553 | $231 |
| Fluticasone-Salmeterol | 11 | $3,795 | $345 |
| Albuterol Sulfate Hfa | 48 | $3,561 | $74 |
| Ventolin Hfa | 14 | $1,502 | $107 |
| Montelukast | 65 | $965 | $15 |
| Fluticasone Propionate | 36 | $950 | $26 |
| Omeprazole | 60 | $775 | $13 |
| Prednisone | 41 | $173 | $4 |
2019: 5 drugs
| Breo Ellipta | 38 | $13,784 | $363 |
| Anoro Ellipta | 16 | $6,635 | $415 |
| Fluticasone Propionate | 22 | $356 | $16 |
| Omeprazole | 17 | $241 | $14 |
| Prednisone | 12 | $43 | $4 |
Money from drug and device companies
$12 in 2020
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Breztri Aerosphere | $12 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Education · 2020-12-03 | Breztri Aerosphere | $12 |
Professional record
- NPI
- 1891139762
- Licence
- CA A161446California A161446: Current · expires 2027-03-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 2025 Soquel Ave, Santa Cruz, CA, 95062
- NPI first listed
- 2013-04-23
- NPI last updated
- 2019-10-02
This is when the NPI record was last certified, not a medical board exam.